Safely and Effectively Managing Sleep Maintenance Insomnia in Older Adults

Program Overview

Sleep maintenance insomnia is the most common form of sleep disturbance encountered and carries the greatest personal and societal burden, especially in older adults. Despite this, there is a huge unmet need associated with managing sleep maintenance insomnia, as shorter-acting agents are ineffective in maintaining sleep and longer-acting agents, especially those that act on the gamma-aminobutyric acid (GABA) receptor, result in next-day residual and hangover effects, which place older adults at risk for falls. Recently, new agents have begun to emerge that act on orexin receptors and have been demonstrated to have fewer residual effects. Clinicians need to be aware of these, and their distinct mechanism of action, so that sleep maintenance insomnia sufferers are more optimally treated with fewer risks of side effects. In this activity, you will learn about the impact and management of sleep maintenance insomnia, including current approaches, as well as novel and emerging treatments.

Credit Expired
CE Credit Expired
Expires: June 20, 2020

Target Audience

This activity has been designed to meet the educational needs of healthcare providers, including psychiatry physicians, PAs, and NPs who diagnose and manage older adult patients with sleep maintenance insomnia.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Describe current challenges associated with managing sleep maintenance insomnia, especially in older and elderly patients
  • Utilize currently available and emerging treatments to manage sleep maintenance insomnia, including those that avoid residual next-day effects, especially in older and elderly populations

Activity Faculty

Russell P. Rosenberg, PhD, DABSM

Founder and Director
Atlanta School of Sleep Medicine and Technology
Atlanta, GA

Supporter Statement

Provider Statement

Disclosure of Financial Relationships

Faculty

Planners and Managers

Method of Participation and Request for Credit

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer Statement

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Copyright Statement

© Copyright 2024. All rights reserved. Developed and managed by RMEI Medical Education, LLC. Laurel Office Plaza | 101 Laurel Road, Suite 200 | Voorhees, NJ 08043 | www.RMEI.com | (866) 770-RMEI

Subscribe

Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources